29
Participants
Start Date
May 5, 2023
Primary Completion Date
November 15, 2025
Study Completion Date
April 29, 2026
Selgantolimod
1.5 mg tablet
Placebo
Matching placebo tablet
Soweto ACTG CRS, Johannesburg
Durban International CRS, Durban
De La Salle Health Science Institute Angelo King Medical Research Center (DLSHSI-AKMRC), Cavite
Weill Cornell Chelsea CRS, New York
Weill Cornell Uptown CRS, New York
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS, Pathum Wan
Univ of Pittsburgh, Pittsburgh
Whitman-Walker Health CRS, Washington D.C.
Greensboro CRS Site# 3203, Greensboro
Chapel Hill CRS, Chapel Hill
The Ponce de Leon Center CRS, Atlanta
Alabama CRS, Birmingham
Vanderbilt Therapeutics (VT) CRS, Nashville
Ohio State University CRS, Columbus
Case CRS Site ID# 2501, Cleveland
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai
Northwestern University CRS, Chicago
Houston AIDS Research Team CRS, Houston
UCSD Antiviral Research Center CRS, San Diego
Cincinnati Children's Hosp / Univ Hosp, Cincinnati
New Jersey Medical School Clinical Research Center CRS, Newark
Columbia P&S CRS, New York
University of Washington AIDS CRS, Seattle
Hospital Nossa Senhora da Conceicao CRS, Porto Alegre
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS Site ID# 12101, Rio de Janeiro
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro
GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS, Port-au-Prince
Barranco CRS, Lima
Joint Clinical Research Centre (JCRC)/Kampala Clinical Research Site, Kampala
Milton Park CRS, Milton Park
National Institute of Allergy and Infectious Diseases (NIAID)
NIH